Iscar for Supplemental Care in Stage IV Lung Cancer

National Institutes of Health (NIH)

Status and phase: Completed; Phase 2

Conditions: Lung Cancer

Treatments: Drug: mistletoe; Drug: Iscar

Study type: Interventional

Funder types: NIH

Identifiers

NCT00079794

R21AT001020-01

Rosenzweig

Details and patient eligibility

About

The purpose of this study it to determine whether supplemental treatment with Iscar improves immune function and quality of life among Stage IV non-small cell lung carcinoma patients receiving conventional chemotherapy. Iscar is an herbal medicine made from the total plant extract of mistletoe. this preparation is already in use in Europe and its use in the US is likely to increase as cancer patients continue to seek alternative therapies.

Full description

See Brief Summary

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Stage IV NSCLC patients who receive standard chemotherapy

Exclusion criteria

• Known allergy to Viscum Album L.
• Concomitant use of other mistletoe products
• Concomitant use of mushroom glucan and proteoglycan extracts
• Concomitant use of thymus extract products
• Inability to self-report quality of life utilizing assessment tools
• Ongoing steroid or ACTH therapy
• Co-morbid immunocompromised state
• Pregnancy
• Participation in other clinical trials

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)